Affiliation:
1. State Research Centre for Preventive Medicine;
I.M. Sechenov First Moscow State Medical University
2. Research Institute of Physico-Chemical Medicine
Abstract
The paper summarizes the specific features of post-marketing studies, which are performed after the medication registration, in the settings close to the real-world clinical practice. In particular, the authors discuss the design and results of the Russian post-marketing study of nifedipine CR (controlled release) — ORIENTIR Study. The aim of the study was to assess antihypertensive effectiveness and tolerability of nifedipine CR in patients with arterial hypertension (AH). Results. The study included 38 doctors from 24 clinical centres in 16 Russian cities, as well as 3179 patients with AH. Mean blood pressure (BP) reduction reached 22,9±6,75/16,56±8,74 mm Hg. Target BP levels were achieved in 94,9 % of AH patients without diabetes mellitus (DM), and in 72,1 % patients with a combination of AH and DM. At the last visit, 98 % of the participants continued taking the study medication. Adverse effects were registered in 1,5 % of the participants. Doctor-assessed effectiveness, tolerability, and therapy compliance for nifedipine CR were “excellent” or “good” in 95,8 %, 96,4 %, and 97,7 % of the patients, respectively. Conclusion. The results of this study are consistent with the data from other post-marketing studies of nifedipine CR, confirming its antihypertensive effectiveness and good tolerability.
Subject
Cardiology and Cardiovascular Medicine
Reference7 articles.
1. Osnovy dokazatel'noi meditsiny. Uchebnoe posobie dlya sistemy poslevuzovskogo i dopolnitel'nogo professional'nogo obrazovaniya vrachei. Pod obshchei redaktsiei akademika RAMN, prof. Oganova R.G. M.: Silitseya-Poligraf 2010; 136 S.
2. Filippova I. Zachem nuzhny nablyudeniya za primeneniem LS. Remedium 2009;3: 11-4.
3. Directive 2001/20/EC of the European parliament and of the council of 4 April. Official J of the Eur Communities 2001: 121-34.
4. Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with longacting calcium channel blockers or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000, 356: 366-72.
5. Martsevich S.Yu., Alimova E.V., Gorbunov V.M. i dr. Effektivnost' novoi lekarstvennoi formy nifedipina prolongirovannogo deistviya — Nifekarda KhL pri lechenii arterial'noi gipertonii. RKZh 2003; 5(43): 55-8.